Another phase II trial (NCT02630368) using VV with cyclophosphamide and avelumab in advanced breast cancer demonstrated prolonged progression-free survival and significantly upregulated immune-related gene expression in human epidermal growth factor receptor 2-positive (HER2+) and TNBC subtypes [89,90]. Here, ERBB2 is linked to breast carcinoma.